HomeInsightsStock Comparison

Cipla Ltd vs Divis Laboratories Ltd Stock Comparison

Cipla Ltd vs Divis Laboratories Ltd Stock Comparison

Last Updated on: Jul 16, 2025

Key Highlights

  • The Latest Trading Price of Cipla Ltd is ₹ 1480 as of 16 Jul 12:40.
  • The P/E Ratio of Cipla Ltd changed from 22 on March 2020 to 22.1 on March 2025 . This represents a CAGR of 0.08% over 6 yearsThe P/E Ratio of Divis Laboratories Ltd changed from 38.3 on March 2020 to 0 on March 2025 . This represents a CAGR of -100.00% over 6 years.
  • The Market Cap of Cipla Ltd changed from ₹ 34103 crore on March 2020 to ₹ 116434 crore on March 2025 . This represents a CAGR of 22.71% over 6 yearsThe Market Cap of Divis Laboratories Ltd changed from ₹ 52763 crore on March 2020 to ₹ 0 crore on March 2025 . This represents a CAGR of -100.00% over 6 years.
  • The revenue of Cipla Ltd for the Mar '25 is ₹ 7019 crore as compare to the Dec '24 revenue of ₹ 7294 crore. This represent the decline of -3.78% The revenue of Divis Laboratories Ltd for the Mar '25 is ₹ 2671 crore as compare to the Dec '24 revenue of ₹ 2401 crore. This represent the growth of 11.25%.
  • The ebitda of Cipla Ltd for the Mar '25 is ₹ 1827 crore as compare to the Dec '24 ebitda of ₹ 2210 crore. This represent the decline of -17.35% The ebitda of Divis Laboratories Ltd for the Mar '25 is ₹ 971 crore as compare to the Dec '24 ebitda of ₹ 825 crore. This represent the growth of 17.7%.
  • The net profit of Cipla Ltd changed from ₹ 996.58 crore to ₹ 1225 crore over 8 quarters. This represents a CAGR of 10.87% The net profit of Divis Laboratories Ltd changed from ₹ 356 crore to ₹ 662 crore over 8 quarters. This represents a CAGR of 36.37% .
  • The Dividend Payout of Cipla Ltd changed from 14.24 % on March 2020 to 25.05 % on March 2025 . This represents a CAGR of 9.87% over 6 yearsThe Dividend Payout of Divis Laboratories Ltd changed from 33.04 % on March 2020 to 0 % on March 2025 . This represents a CAGR of -100.00% over 6 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Cipla Ltd

  • Cipla Limited is one of the leading pharmaceutical companies in India.
  • The Company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs).
  • Cipla's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments.
  • With a rich portfolio, it is deepening presence in the home markets of India, as well as South Africa, North America, and other key regulated and emerging markets.
  • Its 47 manufacturing sites around the world produce more than 50 dosage forms and over 1,500 products across wide range of therapeutic categories. Cipla Limited was incorporated in year 1935 with the name as 'Chemical, Industrial & Pharmaceutical Laboratories Limited'.

About Divis Laboratories Ltd

  • Divi's Laboratories Limited is one of the leading pharmaceutical companies in the world, manufacturing Active Pharmaceutical Ingredients (APIs), Intermediates and Nutraceuticals.
  • The Company is one of the world's largest API companies, with two manufacturing units and a market presence across 100 countries.
  • It is engaged in the manufacture of Active Pharmaceutical ingredients (API's), Intermediates and Nutraceutical ingredients with predominance in exports.
  • In addition to generic business, the Company, through its custom synthesis business, supports innovator pharma companies for their patented products business right from gram scale requirements for clinical trials to launch as well as late life cycle management.
  • It is among the largest pharmaceutical companies in India with a portfolio of approx.

Cipla Ltd News Hub

News

Cipla to conduct board meeting

Cipla will hold a meeting of the Board of Directors of the Company on 25 July 2025. Powere...

Read more

02 Jul 2025 10:19

News

Cipla allots 43,396 equity shares under ESOP

Cipla has allotted 43,396 fully paid-up equity shares of Rs 2 each, pursuant to exercise o...

Read more

27 Jun 2025 11:02

News

Cipla Ltd spurts 0.42%, up for fifth straight session

Cipla Ltd is up for a fifth straight session today. The stock is quoting at Rs 1517.2, up ...

Read more

11 Jun 2025 13:00

News

Jay Precision Pharmaceuticals acquires 26% stake in AMPIN Energy C&I Eighteen

Jay Precision Pharmaceuticals, subsidiary of Cipla, has completed acquisition of 26% stake...

Read more

29 May 2025 18:48

News

Cipla announced incorporation of subsidiary - CiplaRna GmbH' in Germany

Cipla announced that Cipla (EU), UK, a wholly owned subsidiary of the Company, has incorpo...

Read more

29 May 2025 18:50

News

Cipla to convene AGM

Cipla announced that the 89th Annual General Meeting(AGM) of the company will be held on 1...

Read more

14 May 2025 15:08

Divis Laboratories Ltd News Hub

News

Divis Laboratories Ltd up for third consecutive session

Divis Laboratories Ltd is up for a third straight session today. The stock is quoting at R...

Read more

11 Jun 2025 13:05

News

Divis Laboratories Ltd down for fifth straight session

Divis Laboratories Ltd is down for a fifth straight session today. The stock is quoting at...

Read more

02 Jun 2025 13:35

News

Divis Lab inks long-term global pharma deal

As part of the agreement, Divis will manufacture and supply advanced pharmaceutical interm...

Read more

24 May 2025 10:06

News

Divis Lab enters into a LT manufacturing and supply agreement with a global pharma co.

Divis Laboratories has entered into a long term manufacturing and supply agreement with a ...

Read more

24 May 2025 11:34

News

Divis Lab gains after Q4 PAT climbs 23% YoY; recommends final dividend of Rs 30/ share

Revenue from operations grew by 12.24% year on year (YoY) to Rs 2,585 crore in the quarter...

Read more

19 May 2025 10:00

News

Divis Laboratories to convene AGM

Divis Laboratories announced that the 35th Annual General Meeting(AGM) of the company will...

Read more

19 May 2025 17:49

SWOT Analysis Of Cipla Ltd

Strength

3

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Divis Laboratories Ltd

Strength

4

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Cipla Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Divis Laboratories Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Cipla Ltd and Divis Laboratories Ltd

Which company has a larger market capitalization, Cipla Ltd or Divis Laboratories Ltd?

Market cap of Cipla Ltd is 120,427 Cr while Market cap of Divis Laboratories Ltd is 180,214 Cr

What are the key factors driving the stock performance of Cipla Ltd and Divis Laboratories Ltd?

The stock performance of Cipla Ltd and Divis Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Cipla Ltd and Divis Laboratories Ltd?

As of July 16, 2025, the Cipla Ltd stock price is INR ₹1490.9. On the other hand, Divis Laboratories Ltd stock price is INR ₹6788.55.

How do dividend payouts of Cipla Ltd and Divis Laboratories Ltd compare?

To compare the dividend payouts of Cipla Ltd and Divis Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions